Evoke Pharma Q3 sales rise 61%, expects QOL Medical acquisition to close in Q4 2025

Reuters

2025/11/13

<a href="https://laohu8.com/S/EVOK">Evoke Pharma</a> Q3 sales rise 61%, expects QOL Medical acquisition to close in Q4 2025

Overview

Evoke Q3 2025 net product sales rose 61% yr/yr to $4.3 mln
Company to be acquired by QOL Medical for $11.00 per share
Gimoti patent extended to November 2038, ensuring exclusivity

Outlook

Company expects acquisition by QOL Medical to close in Q4 2025
Company anticipates expanded distribution through new pharmacy relationships
Company believes acquisition will enhance growth potential under new leadership

Result Drivers

SALES GROWTH - Net product sales for Q3 2025 increased by 61% yr/yr, driven by expanded pharmacy access and distribution partnerships
EXPANDED ACCESS - New pharmacy relationships with Omnicell and Brentwood Pharmacy enhance distribution

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 EPS		-$0.45
Q3 Net Income		-$1.20 mln
Q3 Operating Expenses		$5.40 mln

Analyst Coverage

The one available analyst rating on the shares is "hold"
The average consensus recommendation for the pharmaceuticals peer group is "buy."

Press Release: ID:nGNX80pkz3

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2583556248"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2583556248\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2583556248?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-13 20:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583556248","market":"fut","top_or_hot":-1,"title":"Evoke Pharma Q3 sales rise 61%, expects QOL Medical acquisition to close in Q4 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/EVOK\">Evoke Pharma</a> Q3 sales rise 61%, expects QOL Medical acquisition to close in Q4 2025</title></head><body><p><span>Overview</span></p><ul><li><p>Evoke Q3 2025 net product sales rose 61% yr/yr to $4.3 mln</p></li><li><p>Company to be acquired by QOL Medical for $11.00 per share</p></li><li><p>Gimoti patent extended to November 2038, ensuring exclusivity</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company expects acquisition by QOL Medical to close in Q4 2025</p></li><li><p>Company anticipates expanded distribution through new pharmacy relationships</p></li><li><p>Company believes acquisition will enhance growth potential under new leadership</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>SALES GROWTH - Net product sales for Q3 2025 increased by 61% yr/yr, driven by expanded pharmacy access and distribution partnerships</p></li><li><p>EXPANDED ACCESS - New pharmacy relationships with <a href=\"https://laohu8.com/S/OMCL\">Omnicell</a> and Brentwood Pharmacy enhance distribution</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$0.45</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$1.20 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$5.40 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The one available analyst rating on the shares is \"hold\"</p></li><li><p>The average consensus recommendation for the pharmaceuticals peer group is \"buy.\"</p></li></ul><p>Press Release: <span>ID:nGNX80pkz3</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Evoke Pharma Q3 sales rise 61%, expects QOL Medical acquisition to close in Q4 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEvoke Pharma Q3 sales rise 61%, expects QOL Medical acquisition to close in Q4 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-13 20:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/EVOK\">Evoke Pharma</a> Q3 sales rise 61%, expects QOL Medical acquisition to close in Q4 2025</title></head><body><p><span>Overview</span></p><ul><li><p>Evoke Q3 2025 net product sales rose 61% yr/yr to $4.3 mln</p></li><li><p>Company to be acquired by QOL Medical for $11.00 per share</p></li><li><p>Gimoti patent extended to November 2038, ensuring exclusivity</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company expects acquisition by QOL Medical to close in Q4 2025</p></li><li><p>Company anticipates expanded distribution through new pharmacy relationships</p></li><li><p>Company believes acquisition will enhance growth potential under new leadership</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>SALES GROWTH - Net product sales for Q3 2025 increased by 61% yr/yr, driven by expanded pharmacy access and distribution partnerships</p></li><li><p>EXPANDED ACCESS - New pharmacy relationships with <a href=\"https://laohu8.com/S/OMCL\">Omnicell</a> and Brentwood Pharmacy enhance distribution</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$0.45</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$1.20 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$5.40 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The one available analyst rating on the shares is \"hold\"</p></li><li><p>The average consensus recommendation for the pharmaceuticals peer group is \"buy.\"</p></li></ul><p>Press Release: <span>ID:nGNX80pkz3</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nL1N3WP0GH:1","article_id":"2583556248","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583556248","pubTimestamp":1763036065,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Evoke Pharma Q3 sales rise 61%, expects QOL Medicalacquisition to close in Q4 2025OverviewEvoke Q3 2025 net product sales rose 61% yr/yr to $4.3 mlnCompany to be acquired by QOL Medical for $11.00 per","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","EVOK":"Evoke Pharma Inc."},"translate_title":"Evoke Pharma第三季度销售额增长61%，预计QOL Medical收购将于2025年第四季度完成","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EVOK":0.9},"content_text":"Evoke Pharma Q3 sales rise 61%, expects QOL Medical acquisition to close in Q4 2025OverviewEvoke Q3 2025 net product sales rose 61% yr/yr to $4.3 mlnCompany to be acquired by QOL Medical for $11.00 per shareGimoti patent extended to November 2038, ensuring exclusivityOutlookCompany expects acquisition by QOL Medical to close in Q4 2025Company anticipates expanded distribution through new pharmacy relationshipsCompany believes acquisition will enhance growth potential under new leadershipResult DriversSALES GROWTH - Net product sales for Q3 2025 increased by 61% yr/yr, driven by expanded pharmacy access and distribution partnershipsEXPANDED ACCESS - New pharmacy relationships with Omnicell and Brentwood Pharmacy enhance distributionKey DetailsMetricBeat/MissActualConsensus EstimateQ3 EPS-$0.45Q3 Net Income-$1.20 mlnQ3 Operating Expenses$5.40 mlnAnalyst CoverageThe one available analyst rating on the shares is \"hold\"The average consensus recommendation for the pharmaceuticals peer group is \"buy.\"Press Release: ID:nGNX80pkz3For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"merge","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}